April 8 response to FDA letter citing MetroGel broadcast ads maintains that the term "skin discomfort" does not minimize side effects of topical rosacea treatment and fairly encompasses "burning, skin irritation and dryness" ("The Pink Sheet" April 6, p. 21).Galderma also disagrees that the term "hypersensitive" is too complicated for consumers to understand. Company says, however, it will list side effects separately and include the term "allergy" in future ads. Galderma also objects to FDA comment that the ad was not adequate because it did not comply with the agency's draft broadcast guidance. "FDA has no authority to enforce a draft guidance or to cite a manufacturer for 'noncompliance' with a draft guidance"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth